Ignite Creation Date:
2025-12-25 @ 2:08 AM
Ignite Modification Date:
2026-01-07 @ 3:18 AM
Study NCT ID:
NCT05171660
Status:
RECRUITING
Last Update Posted:
2025-06-15
First Post:
2021-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2021-1013
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None